Provide feedbackProvide feedback

« Back

Generon begins Phase II trial of investigational treatment for chemotherapy-induced neutropenia

Friday, May 04 2012 | Comments
Evidence Grade 0 What's This?
After receiving clearance from the Food and Drug Administration, Shanghai-based Generon Corp. Ltd. started a Phase II study of F-627 in women with breast cancer who are receiving myelotoxic chemotherapy.

Approximately 200 patients will be included in the randomized, open-label trial. The main objective is to evaluate the efficacy and safety of various once-per-cycle dosing of F-627 as compared with standard dosing of Amgen Inc.'s Neulasta (pegfilgrastim) in patients with breast cancer who are undergoing myelotoxic chemotherapy.

Generon described F-627 as a newer generation recombinant human granulocyte colony-stimulating factor (G-CSF) that helps patients with cancer to recover from chemotherapy-induced neutropenia.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.